drugset / Trial / NCT03121833
Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma
Non-randomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled (2: 1), multicenter clinical phase II clinical trial evaluating the efficacy and safety of Endostar combined with chemotherapy for stage IV soft tissue sarcoma.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2019-12-20
- Completion
- 2019-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Ifosfamide | Small molecule | — | — |
| Background | Pirarubicin | Small molecule | 75 mg/m2 | — |